In case you haven’t been keeping up-to-date with the latest news in the biotechnology regulatory system (and how could you not?), the system is under revision. As part of the new Coordinated Framework the FDA stated it would clarify how it will deal with the hot-button topic of genome editing, and update its guidance documents accordingly. As part of this process the FDA opened
a docket on regulations.gov to receive public comments about the issue. As you might expect, a large majority of the comments have been less than scientific.
They are asking for your evidence-based input. Please give it to them!